| Field | Specification |
|---|---|
| Applications | |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
OneScript® Plus Reverse Transcriptase is a Moloney-Murine Leukemia Virus (M-MLV) Reverse Transcriptase with genetic modifications to abolish RNase H activity to achieve thermal stability. This special mutant enzyme offers higher cDNA yields, longer cDNA up to 12 kb, and is able to perform under high temperatures (50°C - 55°C), facilitating the elimination of secondary structures associated with GC-rich RNA templates.
OneScript® Plus is formulated with abm’s RNaseOFF Ribonuclease Inhibitor (Cat. No. G138) offering improved resistance to oxidation compared to the high oxidation-sensitive human RNase inhibitors. RNaseOFF is stable even under very low concentrations of DTT (< 1 mM), making it the best choice for ultimate RNA protection.
Product Features:
- High thermostability at 50-55°C/122-131°F
- Synthesize cDNA up to 12 kb
- 10-15 minutes reaction time
- OneScript® Plus cDNA Synthesis Kit (Cat. No. G236) also available
- Pair with BlasTaq™ 2X PCR MasterMix (Cat. No. G895) for Two-Step RT-PCR workflows
- Included in abm's PCR Buffet Program
| Product Component | Quantity |
|---|---|
| OneScript® Plus Reverse Transcriptase | 100 rxn (100 µl) |
| 5X RT Buffer | 400 µl |
![]() |
ISO 13485:2016 MDSAP Certified |
|
This product is equivalent to RScript Plus Reverse Transcriptase (Cat. No. G237EU). |
| Specification | Value |
|---|---|
| Enzyme Type | Reverse Transcriptase |
| Format | Enzyme Only |
| RT Origin | M-MLV |
| Max cDNA Length | 12 kb |
| Storage Conditions | Store at -20°C. |
Chaudhuri E, Dash S, Balasubramaniam M, et al. (2020) The HIV-1 capsid-binding host factor CPSF6 is post-transcriptionally regulated by the cellular microRNA miR-125b. Journal of Biological Chemistry, 295, 5081–5094. 10.1074/jbc.RA119.010534
Gallardo CM, Wang S, Montiel-Garcia DJ, et al. (2021) MrHAMER yields highly accurate single molecule viral sequences enabling analysis of intra-host evolution. Nucleic Acids Research, 49, e70. 10.1093/nar/gkab231
Han J, Zuo J, Zhang X, et al. (2022) TRIM29 is differentially expressed in colorectal cancers of different primary locations and affects survival by regulating tumor immunity. Journal of Gastrointestinal Oncology, 13, 1132–1151. 10.21037/jgo-22-365
